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with oligometastases (p = 0.03). Significant differences were 
also seen between the 2 oligometastatic patient groups with 
and without more intense thoracic treatment (median 19.7 
vs. 7.6 months, p = 0.004). Further significant predictors of 
survival in patients with oligometastases were nodal stage 
(p = 0.028) and weight loss (p = 0.045). Trends were seen for 
T stage (p = 0.058) and performance status (p = 0.07).  Con-
clusion: Oligometastatic NSCLC was diagnosed in a relevant 
proportion of patients; therefore, warranting prospective 
studies are recommended. Such studies are also needed to 
confirm the treatment-dependent survival differences ob-
served in our patient population.  © 2014 S. Karger AG, Basel 
 Introduction 
 Distant metastatic stage IV non-small cell lung cancer 
(NSCLC) is a common and serious diagnosis, with sur-
vival typically limited to months rather than years  [1] . 
However, the patterns of spread and the total tumor bur-
den vary widely  [2] . Some patients might initially present 
with multiple liver, adrenal gland, and bone metastases, 
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 Abstract 
 Objective: To report the incidence, patterns of care, and out-
comes of oligometastatic non-small cell lung cancer (NSCLC) 
in a rural practice setting in Norway.  Materials and Methods: 
A retrospective analysis was conducted of all patients with 
stage IV NSCLC at the initial diagnosis who received active 
treatment in the central part of Nordland, a rural county in 
northern Norway, during the period of 2006–2012. We ana-
lyzed overall survival and prognostic factors.  Results: The ini-
tial study population included 113 patients with stage IV dis-
ease who received active therapy; of these, 23 (20%) had 
oligometastatic spread (a maximum of 3 metastases to 1 or-
gan). The median age was 71 years. Of the 23 patients, 16 
(70%) did not receive radical or at least moderately aggres-
sive local treatment for their thoracic disease. Of the remain-
ing 7 patients, 4 (17.4%) did not receive systemic therapy. 
The median actuarial survival was 5.6 months in patients 
with more advanced metastases and 11.7 months in those 
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while others harbor a solitary brain metastasis  [3] . It has 
long been recognized that patients with a solitary brain 
metastasis and limited thoracic disease might experience 
favorable long-term survival after effective local therapy 
 [4] . Historically, cohort studies published during the 
1980s with treatment dating back to even earlier decades 
already described the concept of surgical treatment in 
NSCLC with a solitary brain metastasis, which resulted in 
variable rates of 5-year survival  [5] . Later on, stereotactic 
radiosurgery was used for some patients with brain me-
tastases, and more recently, the introduction of extracra-
nial stereotactic ablative radiotherapy has enabled us to 
provide noninvasive highly efficacious local therapy to 
different sites of oligometastases  [6] . The latter paradigm 
is based on the hypothesis that subgroups of patients with 
stage IV NSCLC might be candidates for aggressive local 
treatment based on disease extent and the feasibility of 
such therapy, and that those with oligometastatic disease 
might fare better than the majority of patients, i.e. those 
with widespread distant metastases. The exact definition 
of oligometastatic NSCLC remains to be agreed upon. It 
is also not fully understood whether differences in tumor 
biology, treatment approaches, or both can adequately 
explain the different course of the disease, or whether lo-
cal treatment at all sites of disease should be attempted. 
Most previous studies emanated from large institutions 
that might or might not see patients who are comparable 
to real-world NSCLC cohorts, due to referral characteris-
tics  [7–9] . Therefore, we evaluated an unselected patient 
group from a rural area treated with or without local ther-
apies of different efficacy. Based on previous studies, we 
hypothesized that radical or at least moderately aggres-
sive local treatment of the primary tumor and the in-
volved regional lymphatics (T and N sites) might improve 
survival.
 Subjects and Methods 
 Since this is a retrospective quality-of-care analysis, no approv-
al from the Regional Committees for Medical and Health Research 
Ethics (REK) was necessary. This retrospective study included all 
patients with stage IV NSCLC who received care at one of Nord-
land Hospital Trust’s (NHT) 3 somatic hospitals in the county of 
Nordland, northern Norway. The NHT is owned by the Ministry 
of Health and Care Services and is administered through a region-
al trust (North Norway Regional Health Authority Trust). It pro-
vides specialist health care Services to approximately 112,000 in-
habitants, i.e. roughly 50% of the population of the county (a geo-
graphically widespread, largely rural area) including its main city 
Bodø. The remaining areas of the county (extreme north and 
south) are served by other hospitals. The NHT is the exclusive on-
cology care provider for the region where no private pulmonology 
or oncology services are available. These facts and the structure of 
the Norwegian health care system allow for evaluation of unselect-
ed patient groups almost comparable to large population-based 
registries, albeit with a limited size. We used the electronic data-
bases of the Departments of Oncology and Palliative Medicine, 
Pulmonology, and Thoracic Surgery and the Division of Internal 
Medicine of the NHT to identify all patients treated for histologi-
cally confirmed NSCLC between 2006 and 2012 and selected those 
with stage IV disease at the initial diagnosis, irrespectively of the 
treatment approach unless no active treatment was given (n = 113). 
All medical records including death certificates and demographic 
data were available in the hospital’s electronic patient record sys-
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tem and were reviewed starting with the first referral for suspected 
lung cancer. Clinical and imaging follow-up was performed every 
2–3 months or earlier in cases of symptom progression. All pa-
tients were Caucasian and covered by the national public insur-
ance system. Their treatment was discussed by a multidisciplinary 
tumor board which met on a weekly basis. Tumor, node, and me-
tastases (TNM) staging was applied as described by Goldstraw et 
al.  [10] . We defined oligometastatic disease as in the recent study 
by Griffioen et al.  [7] , i.e. 1–3 synchronous metastases found in 
only 1 organ (e.g. up to 3 brain metastases, or uni- or bilateral ad-
renal gland metastases, or up to 3 contralateral lung metastases, or 
up to 3 liver metastases). Note that separate tumor nodule(s) in the 
same lobe as the primary tumor are defined as T3, and that separate 
tumor nodule(s) in a different ipsilateral lobe are defined as T4. 
Patients with previous malignancies were not included because ra-
diological staging rather than systematic biopsies of metastases 
was performed (in such cases, metastases might be caused by 
NSCLC or the previous malignancy). Radiological staging includ-
ed computed tomography (CT) scans of the chest, abdomen, pel-
vis, and head and an isotope bone scan. Supplemental ultrasound, 
magnetic resonance imaging (MRI), or positron emission tomog-
raphy (PET) was added as appropriate to define the treatment 
strategy. For example, if the CT scans already showed multiple 
brain and multiple liver metastases, no further imaging was or-
dered because the patient would receive primary systemic treat-
ment and whole-brain radiotherapy in any case. If the initial stag-
ing showed amenability to a surgical approach, PET-CT and brain 
MRI were considered appropriate  [11] . Radical or at least moder-
ately aggressive local treatment consisted of surgery, chemoradia-
tion, or radiotherapy at a biological dose equivalent to at least 13 
fractions of 3 Gy  [7] . None of our patients received extracranial 
stereotactic ablative radiotherapy. Radiosurgery for brain metasta-
ses was available.
 Statistical Analysis  
 The IBM SPSS Statistics 21 software package (IBM SPSS Statis-
tics, Somers, N.Y., USA) was used for the database and statistical 
analyses. Actuarial survival from the initial imaging diagnosis was 
analyzed according to the Kaplan-Meier method. Survival curves 
were compared using a log-rank test. Only 2 patients were alive at 
the time of analysis (follow-up: 15 and 17 months, respectively). 
Initially, we had planned multivariate survival analyses (Cox re-
gression). However, the final number of patients with oligometas-
tases was not sufficient. The following variables were analyzed uni-
variately: age, sex, weight loss, comorbidity, smoking status, T 
stage, N stage, TNM stage (7th edition), initial pattern of meta-
static disease, histology, initial management strategy, number of 
lines of systemic treatment, and use of thoracic radiotherapy. 
 Results 
 The initial study population consisted of 113 patients 
with stage IV disease who received active therapy; of 
these, 23 (20%) had oligometastatic spread (a maximum 
of 3 metastases to 1 organ). Seven of the 23 oligometastat-
ic-spread cases involved the brain, 7 the adrenal gland(s), 
5 the contralateral lung, 3 the skeleton, and 1 the liver. 
The median age was 71 years (range 56–81). Four patients 
had an excellent performance status (ECOG 0); 10 were 
categorized as ECOG 1, and the remaining 9 were ECOG 
2. Nineteen patients were males and 4 were females. No 
mutation was detected in the routine assessment of epi-
dermal growth factor receptor mutations. The baseline 
characteristics of the patients are given in  table  1 . The 
majority of the patients (n = 16; 70%) did not receive rad-
ical or at least moderately aggressive local treatment at 
their T and N sites ( table 2 ). The details regarding all 7 
patients who received such treatment are given in  table 3 . 
Most of these patients had brain metastases and a limited 
thoracic disease extent. Squamous cell carcinoma was 
slightly overrepresented. All 7 patients developed disease 
progression during follow-up. 
 Of the 23 cases, 5 (22%) were not given systemic treat-
ment because 3 of them were of an advanced age and had 
comorbidities and the others chose not to receive such 
treatment. Ten patients received 1 line of systemic treat-
ment (2 lines, n = 5; 3 lines, n = 2, and unknown number, 
n = 1). Seven patients never received thoracic radiother-
apy. The median actuarial survival was 11.7 months (all 
23 patients), which was significantly better than the sur-
vival of patients with more advanced metastases (median 
5.6 months, 1-year rate 21%, p = 0.03). Significant differ-
Parameter No oligometastases 
(n = 90)
Oligometastases
Radical or at least moderately 
intense treatment (n = 7)
Other treatment
(n = 16)
Received systemic therapy 83 43 94
More than one line of systemic therapy 26 0 50
Received thoracic radiotherapya 43 100b 69
 Values are presented as percentages. a Irrespective of the dose. b Including patients treated with surgical resection.
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ences were seen between the 2 oligometastatic patient 
groups with and without radical or at least moderately 
aggressive thoracic treatment (median 19.7 vs. 7.6 months, 
p = 0.004;  fig. 1 ). The 1-year survival rate was 86% com-
pared to 25%. Further significant predictors of survival 
were N stage (p = 0.028) and weight loss (p = 0.045). 
Trends were seen for T stage (p = 0.058) and performance 
status (p = 0.07). 
 Discussion 
 In our general practice, a clinically significant propor-
tion of patients with NSCLC had oligometastatic disease 
(20% had 1–3 metastases limited to 1 site), and this dis-
ease state appeared to be associated with better survival. 
The common sites of oligometastases were the brain and 
adrenal glands, i.e. mainly sites that are accessible for sur-
gery or stereotactic ablative radiotherapy. The majority of 
patients had thoracic stage I-IIIA disease, and hence they 
were eligible for aggressive local treatment as long as their 
general condition, organ function, and comorbidity al-
lowed for such therapy. These findings suggest that tho-
racic surgery or (chemo)radiotherapy should be consid-
ered using a minimum radiation dose equivalent to at 
least 39 Gy in 3-Gy fractions that could provide meaning-
ful local control, although most patients received more 
intense treatment. Despite survival improvement after 
such treatment, thoracic failure was common.
 Our study is different from previous studies in terms of 
aspects such as practice setting and the use of radical treat-
ment approaches  [7–9, 12] . Some studies also included 
more patients, i.e. up to 78. No consistent prognostic fac-
tors were identified. In the study by Griffioen et al.  [7] , 61 
patients from 2 centers were treated with radical intent at 
all sites of disease, unlike our study where inconsistent 
 Table 3.  Details regarding patients who received radical or at least moderately intense local treatment of the primary tumor and the in-

















Female 74 Never 0 <5 Adeno. T2 N1 Brain (1) CT/MRI OP/OP New BM 25.9
Male 69 Quit 1 1 None Squamous T2 N0 Spine (1) PET-CT RT high/low Primary 19.0
Male 80 Quit 1 2 5 – 10 Squamous T3 N1 C lung (1) CT RT low/low Primary 9.4
Male 63 Quit 1 2 None Squamous T4 N0 Brain (1) CT/MRI RCT high/low New BM 15a
Male 64 Quit 1 0 None Unspecified T3 N2 Brain (2) CT/MRI RCT high/high Primary 16.2
Male 79 Quit 1 1 >10 Adeno. T2 N1 Brain (1) CT/MRI OP/RT high Bothb 19.7






























 Quit 1 = Quit at least 1 year before the diagnosis; Quit <1 = quit 
less than 1 year before the diagnosis; PS = performance status;
OS = overall survival; RT = radiotherapy; low = biologically equiva-
lent dose of less than 60 Gy in 2-Gy fractions, α-/β-value 10 Gy;
high = at least 60 Gy in 2-Gy fractions (includes brain radiosurgery); 
RCT = concomitant chemo- and radiotherapy; OP = surgical resec-
tion; C = contralateral; BM = brain metastases; CTx = platinum-
based doublet chemotherapy; UNK = unknown pattern of progres-
sion; Adeno. = adenocarcinoma. a Alive at the last follow-up. b Deve-
loped new brain metastases and later also mediastinal relapse.
 Fig. 1. Actuarial survival of the 2 oligometastatic patient groups 
with (labeled 1) and without (labeled 0) radical or at least moder-
ately aggressive thoracic treatment (median 19.7 vs. 7.6 months,
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management approaches were used. The median survival 
rate of 11.7 months in the study by Griffioen et al.  [7] was 
comparable to the 13.3 months in our study, in which not 
all patients had radical treatment. However, patients with 
a resected primary or a small radiotherapy target volume 
had better survival. The 1-year survival rate of 54% in our 
study was slightly lower than the 62% reported by Lopez-
Guerra et al.  [9] , who reported on 78 patients, all treated 
with definitive chemoradiation ( ≥ 45 Gy) to the primary 
site, 44 of whom also had definitive local treatment for the 
metastases. Performance status, a higher radiation dose, 
and a smaller thoracic gross tumor volume predicted im-
proved survival. Hasselle et al.  [13] treated 25 patients 
with 5 or fewer metastases with hypofractionated image-
guided radiotherapy directed at all sites of active disease. 
The median survival was 22.7 months, while the progres-
sion-free survival was only 7.6 months. Patients who had 
more than 2 sites treated had a shorter progression-free 
survival. Local control of the irradiated sites was much 
better than distant control (66% compared to 32% at 18 
months of follow-up). An earlier series by Khan et al.  [14] 
included 23 patients with 1–2 metastases treated with che-
motherapy and curative local-regional treatment. The 
median survival was 20 months, as in the series of 38 pa-
tients reported by Cheruvu et al.  [15] . The latter study in-
cluded patients with more advanced disease (up to 8 me-
tastases) treated with stereotactic radiotherapy. A pro-
spective phase II trial was reported from the MAASTRO 
clinic, The Netherlands  [8] . It included 40 patients with 
less than 5 metastases who were eligible for surgery or rad-
ical radiotherapy. The majority had local stage III disease 
and brain metastases (87% had a single metastasis). The 
median survival was 13.5 months. No prognostic factors 
could be identified. The median survival in all of the stud-
ies discussed here was longer than in our study and varied 
between 13.5 and 22.7 months. In their systematic review, 
Ashworth et al.  [6] included 2,176 patients from 49 stud-
ies. Of these, 60% included patients with brain metastases 
only. Patients with synchronous and metachronous pre-
sentations were eligible. The median overall survival was 
14.8 months. Significant prognostic factors were: defini-
tive treatment of the primary tumor, N stage, and a dis-
ease-free interval of at least 6–12 months. As correctly 
stated by the authors, the treatment of oligometastatic 
NSCLC is based on low levels of evidence and therefore 
randomized controlled trials are needed. Given that the 
median survival is still limited to less than 2 years and dis-
tant control is difficult to achieve, integration of innova-
tive approaches appears necessary  [16] .
 The limitations of our study include the selection of 
one particular definition for oligometastatic NSCLC from 
the existing literature, the retrospective nature of the 
study, the inclusion of PET-CT only if the results would 
have impacted management, and the variable treatment 
approaches used. Furthermore, the final study sample 
was small. The latter fact hampered subgroup and multi-
variate analyses. A large population-based study of data 
from the Cancer Registry of Norway (www.kreftregister-
et.no) would have been of interest; however, this database 
does not contain data on the number of metastases or 
treatment intensity.
 Conclusion 
 Our data confirmed the clinical significance of oligo-
metastatic NSCLC in a different practice setting as well as 
the median survival results reported by larger centers. 
Defining the most suitable treatment approach (surgery, 
stereotactic ablative radiotherapy, or chemoradiation) re-
quires systematic research efforts including randomized 
trials based on standardized staging.
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